On September 9, 2026 Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, reported that more than 35 abstracts featuring data from its multiple myeloma portfolio will be presented at the 2026 International Myeloma Society (IMS) Annual Meeting in Glasgow, Scotland from September 23 to 26. The presentations span approved and pipeline therapies across multiple stages of disease. They feature long-term follow-up and Phase 3 analyses evaluating outcomes in earlier treatment settings, highlighting advances that contribute to deeper and more durable responses and support the company’s ambition toward potential cures.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leadership comments on redefining what’s possible for patients with multiple myeloma

"Multiple myeloma treatment has advanced significantly, but our ambition is to keep pushing beyond disease control toward patient outcomes that were once difficult to imagine," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "The breadth of new data at IMS reflect our focus on bringing highly effective therapies into earlier treatment settings, generating long-term follow-up that deepens our understanding of durable responses, and building the scientific understanding needed to further progress potential cures."

Key presentations include:

New ≥ 5-year follow-up from the Phase 2 CARTITUDE-2 Cohort A study evaluating CARVYKTI (ciltacabtagene autoleucel; cilta-cel) as a single infusion in patients with relapsed or refractory multiple myeloma treated as early as second line (1-3 prior lines) (Abstract #PA-288)
New analyses from the Phase 3 MajesTEC-3 study further evaluates overall survival, progression and non-relapse mortality with TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma treated as early as second line (1-3 prior lines), with mixture cure modeling (MCM) estimating >85% statistical cure fractions and suggesting the potential to redefine long-term survival expectations for a substantial proportion of patients (Abstract #OA-49 and Abstract #OA-58)
Results from the Phase 3 MonumenTAL-3 study evaluating TALVEY (talquetamab-tgvs) in combination with DARZALEX FASPRO, with or without pomalidomide, versus DARZALEX FASPRO, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma [Encore of EHA (Free EHA Whitepaper) 2026], as well as results from the Phase 2 MajesTEC-5 TALVEY induction arm evaluating TALVEY plus DARZALEX FASPRO and lenalidomide as induction therapy in transplant-eligible patients with newly diagnosed multiple myeloma. (Abstract #PA-350 and Abstract #OA-51)
Long-term outcomes from the Phase 3 PERSEUS study evaluating DARZALEX FASPRO in a Dara-VRd regimen vs. VRd (bortezomib, lenalidomide and dexamethasone) in transplant-eligible patients with newly diagnosed multiple myeloma (Abstract #LBA-07)
Updated safety and efficacy data for ramantamig (JNJ-5322), an investigational BCMA and GPRC5D trispecific antibody, at the recommended Phase 2 dose, with new data demonstrating feasibility of outpatient dosing in patients with relapsed or refractory multiple myeloma (Abstract #OA-70)
A complete list of Johnson & Johnson–sponsored abstracts is available on JNJ.com.

About Multiple Myeloma

Multiple myeloma is a complex blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.1 In multiple myeloma, these clonal plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors.2 Multiple myeloma is the second most common blood cancer worldwide.3 More than 180,000 new cases of multiple myeloma are diagnosed globally each year.4 People living with multiple myeloma have a 5-year survival rate of 59.8%.5 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections.6,7 In recent years, overall survival has improved from years to decades, with effective treatment options now available across every stage and line of therapy.

(Press release, Johnson & Johnson, SEP 9, 2026, View Source [SID1234670668])

On September 9, 2026 Electra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, reported the promotion of Chris Clark, CFA, to Chief Financial Officer. Mr. Clark joined Electra in December 2025 as Executive Vice President, Strategy and Finance, bringing with him more than two decades of life sciences investment experience.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Since joining Electra, Chris has played an instrumental role in shaping our capital strategy and strengthening our position within the healthcare investment community," said Kathy Dong, Pharm.D., MBA, President and Chief Executive Officer of Electra Therapeutics. "As we advance ipsoprubart through its global registrational program in secondary hemophagocytic lymphohistiocytosis and expand our clinical pipeline of precision immune cell depletion therapies, Chris’ leadership, institutional investment experience, and understanding of the capital markets will be critical to guiding our financial and business strategies through our next phase of growth."

Mr. Clark has more than 20 years of expertise evaluating and financing biopharmaceutical companies across therapeutic areas, stages of development and market capitalizations. Prior to joining Electra, he spent 18 years at RS Investments, a subsidiary of Victory Capital, where he served as Portfolio Manager and Equity Analyst focused on healthcare and led investments in biopharmaceutical and life sciences companies across multiple fund strategies. Earlier in his career, Mr. Clark served as a Research Associate at TIAA-CREF, where he focused on global pharmaceutical companies, and as a Research Assistant at Dresdner RCM. He earned a Bachelor of Arts in Economics from the University of Virginia and is a Chartered Financial Analyst (CFA).

"I am honored to step into this new and expanded role, working alongside our talented and passionate team to advance Electra’s strategic and financial priorities, progress our programs, and ultimately serve the many patients with immune-mediated diseases and cancer who are in need of better treatment options," said Mr. Clark.

(Press release, Electra Therapeutics, SEP 9, 2026, View Source [SID1234670667])

On September 9, 2026 Alivexis, Inc. ("Alivexis"), a preclinical-stage computation-driven drug discovery company, reported it will present our recent data from MOD-D, one of our drug discovery programs, at the 85th Annual Meeting of the Japanese Cancer Association, to be held September 24th-26th in Kyoto, Japan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our presentation will focus on the pharmacological profile of AL003626, Alivexis’ highly potent novel WDR5 inhibitor, and its therapeutic activity in various MYC-driven cancers, in the session entitled "Novel Therapeutic Strategies Targeting Cancer Vulnerabilities".

Alivexis’ presentation details are as follows:
Title: Development of AL003626, a Novel WDR5 Inhibitor Targeting the WDR5–MYC Axis for the Treatment of MYC-Driven Cancers
Presentation Number: E-1063
Authers: Masahiro Matsuki, Takafumi Shimizu, Taisuke Takahashi, Blake Mertz, William Sinko, and Yoh Terada
Presentation Date/Time: Thursday, September 24th, 12:50-14:05 (JST)
Venue: Kyoto International Conference Center, Room 12 (2F Room J)

(Press release, Alivexis, SEP 9, 2026, View Source [SID1234670666])

On September 9, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported the release of a new installment of its CEO Corner series featuring Chief Executive Officer Thomas K. Equels discussing the Company’s scientific strategy and continued advancement of Ampligen (rintatolimod) in pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the CEO Corner, Equels discusses the significant challenges associated with pancreatic cancer, including its highly immunosuppressive – or "cold" – tumor microenvironment, which can prevent the immune system from mounting an effective response and has historically limited the effectiveness of many immunotherapy approaches.

Ampligen, AIM’s investigational TLR3 agonist, is designed to activate innate immunity and help reshape the tumor microenvironment, potentially making tumors more responsive to checkpoint inhibition. Based on existing data, AIM believes Ampligen may have a broad-spectrum synergistic effect with both PD-1 checkpoint inhibitors such as pembrolizumab, and PD-L1 checkpoint inhibitors such as durvalumab.

This scientific rationale is being evaluated through the Company’s ongoing Phase 2 DURIPANC study, which is assessing Ampligen in combination with AstraZeneca’s durvalumab as maintenance therapy following standard-of-care treatment in patients with pancreatic cancer. AIM believes the study has the potential to provide important insights into patient selection, biomarker identification and the characteristics of patients who may derive the greatest clinical benefit, helping inform the design of a potential future pivotal development program.

"Pancreatic cancer remains one of oncology’s most difficult diseases, in large part because its immunosuppressive tumor microenvironment creates significant barriers to effective immune responses," said Equels. "Our strategy with Ampligen is designed to address that underlying biology by activating innate immunity and potentially making these tumors more responsive to checkpoint inhibition. As we continue to advance DURIPANC, biomarker research and our broader clinical development strategy, we believe the data generated can further strengthen our understanding of Ampligen’s mechanism of action and its potential role in addressing this significant unmet medical need."

Beyond DURIPANC, AIM continues to build a broader body of scientific and clinical evidence supporting Ampligen through collaborations with leading institutions, ongoing biomarker research, expansion of its intellectual property portfolio and continued regulatory engagement.

Looking ahead in DURIPANC, the Company expects primary endpoint analyses, continued biomarker evaluations and overall survival follow-up. It also plans future regulatory interactions to provide additional opportunities to evaluate Ampligen’s potential and refine AIM’s long-term pancreatic cancer development strategy.

The latest CEO Corner segment is now available on the Company’s website here.

(Press release, AIM ImmunoTech, SEP 9, 2026, View Source [SID1234670665])

On September 9, 2026 Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, reported the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. ("Exelixis").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The milestone achievement is related to a preclinical milestone event for XB404 and resulted in a $2.0 million milestone payment from Exelixis. XB404, built with Adagene’s SAFEbody masking technology, is designed to deliver a cytotoxic payload to ROR1/2-expressing tumors while minimizing on-target, off-tumor side effects. An additional payment to Adagene was triggered by the selection of candidates for another SAFEbody antibody-drug conjugate (ADC) program. Exelixis has the right to utilize Adagene’s SAFEbody technology platform to generate masked monoclonal antibodies for the development of masked ADC candidates.

Adagene is eligible to receive development and commercialization milestones and royalties on net sales of products developed.

(Press release, Adagene, SEP 9, 2026, View Source [SID1234670664])